ContraFect Gross Profit
Gross Profit of ContraFect (CFRXQ) as of Oct 19, 2026.
Get this data via API
Financial Data API
Gross Profit
0.00USD
Last updated:
Gross Profit of ContraFect is 2022 0.00 USD. Gross Profit of ContraFect was 2021 0.00 USD. It decreases by % lower compared to the previous year.
The ContraFect Gross Profit history
3 Years
10 Years
25 Years
Max
GROSS MARGIN (%)
Date
GROSS MARGIN (%)
Jan 1, 2018
0.00 base
Jan 1, 2019
0.00 base
Jan 1, 2020
0.00 base
Jan 1, 2021
0.00 base
Jan 1, 2022
0.00 base
Jan 1, 2023 (e)
0.00 base
Jan 1, 2024 (e)
0.00 base
Jan 1, 2025 (e)
0.00 base
| YEAR | GROSS MARGIN (%) |
|---|---|
| 2025 est | - |
| 2024 est | - |
| 2023 est | - |
| 2022 | - |
| 2021 | - |
| 2020 | - |
| 2019 | - |
| 2018 | - |
| 2017 | - |
| 2016 | - |
| 2015 | - |
| 2014 | - |
| 2013 | - |
| 2012 | - |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
ContraFect Revenue
ContraFect Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
0.00 USD
-31.12 M USD
-37.68 M USD
Jan 1, 2019
0.00 USD
-27.87 M USD
-12.79 M USD
Jan 1, 2020
0.00 USD
-34.24 M USD
-28.16 M USD
Jan 1, 2021
0.00 USD
-47.27 M USD
-20.28 M USD
Jan 1, 2022
0.00 USD
-58.49 M USD
-65.15 M USD
Jan 1, 2023 (e)
0.00 USD
-32.24 M USD
-37.91 M USD
Jan 1, 2024 (e)
0.00 USD
-30.90 M USD
-16.53 M USD
Jan 1, 2025 (e)
0.00 USD
-34.40 M USD
-12.23 M USD
ContraFect Margins
ContraFect stock margins
The ContraFect margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ContraFect. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ContraFect.
3 Years
5 Years
10 Years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
0.00 %
- %
- %
Jan 1, 2019
0.00 %
- %
- %
Jan 1, 2020
0.00 %
- %
- %
Jan 1, 2021
0.00 %
- %
- %
Jan 1, 2022
0.00 %
- %
- %
Jan 1, 2023 (e)
0.00 %
- %
- %
Jan 1, 2024 (e)
0.00 %
- %
- %
Jan 1, 2025 (e)
0.00 %
- %
- %
ContraFect Stock analysis
What does ContraFect do? ContraFect Corp, based in Yonkers, New York, is a clinical-stage biotechnology company focused on developing direct lytic agents (DLAs) such as lysins and amurin peptides to treat life-threatening antibiotic-resistant infections. The company, listed in 2014, employs 23 people and is advancing its lead candidate exebacase (CF-301) for MRSA bloodstream infections and chronic prosthetic joint infections, alongside CF-370 targeting gram-negative bacteria. ContraFect is one of the most popular companies on Eulerpool.
Frequently Asked Questions about ContraFect stock
On Eulerpool you can find the complete historical development of Gross Profit ContraFect since 2006 – with annual values, charts, and detailed analysis.
Gross Profit is the revenue remaining after deducting the cost of goods sold. It shows how efficiently a company uses its resources to produce goods or services.
Gross Profit's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Gross Profit's ContraFect historically and in real time.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Income Statement — ContraFect
All Key Metrics — ContraFect
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth